An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Seoul National University Hospital, Seoul

Severance Hospital Yonsei University Health System, Seoul

Weill Medical College of Cornell University, New York

Mercy Medical Center, Baltimore

Hospital General Universitario Gregorio Maran, Madrid

Southern Therapy and Advanced Research LLC, Jackson

Kyungpook National University Hospital, Daegu

Henry Ford Health System, Novi

Pusan National University Hospital, Busan

The Liver Institute at Methodist Dallas Medical Center, Dallas

American Research Corporation, San Antonio

Pinnacle Clinical Research- SA, San Antonio

University of Colorado Anschutz, Aurora

Arizona Liver Health, Chandler

University of California Davis, Sacramento

Massachusetts General Hospital, Boston

Inje University Busan Paik Hospital, Busan

NIHR BRC Centre for Liver and Gastrointestinal Research Birmingham, Birmingham

The Royal Free London NHS Foundation Trust, London

Kings College Hospital, London